- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05653219
En studie av effektivitet och säkerhet av Ianalumab kontra placebo utöver Eltrombopag hos patienter med primär immun trombocytopeni som misslyckades med steroider (VAYHIT2)
En fas 3 randomiserad, dubbelblind studie av Ianalumab (VAY736) kontra placebo som tillägg till Eltrombopag hos patienter med primär immun trombocytopeni (ITP) som hade otillräckligt svar eller återfall efter första linjens steroidbehandling (VAYHIT2)
The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a multicenter, randomized, double-blinded phase 3 study to assess efficacy and safety of two different doses of ianalumab versus placebo in addition to eltrombopag in adults with primary ITP (platelet count <30 G/L) who failed previous first-line treatment with corticosteroids.
After completion of the screening period, the participants will enter the randomized treatment period (ianalumab/placebo with eltrombopag) followed by the eltrombopag tapering period. Afterwards, all participants will enter the follow-up period to be monitored for efficacy and safety or safety only depending on how the participants responded to the study treatment.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
CABA, Argentina, C1181ACH
- Novartis Investigative Site
-
-
-
-
Namur
-
Yvoir, Namur, Belgien, 5530
- Novartis Investigative Site
-
-
West Vlaanderen
-
Roeselare, West Vlaanderen, Belgien, 8800
- Novartis Investigative Site
-
-
-
-
-
Makati City, Filippinerna, 1229
- Novartis Investigative Site
-
Quezon, Filippinerna, 1102
- Novartis Investigative Site
-
-
-
-
-
Blois, Frankrike, 41000
- Novartis Investigative Site
-
Le Mans, Frankrike, 72000
- Novartis Investigative Site
-
-
-
-
Arizona
-
Yuma, Arizona, Förenta staterna, 85364
- Yuma Regional Medical Center
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- University of Colorado Anschutz
-
-
Illinois
-
Evanston, Illinois, Förenta staterna, 60201
- Endeavor Health
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Boston Medical Center
-
Worcester, Massachusetts, Förenta staterna, 01665
- UMASS Memorial Medical Center
-
-
Michigan
-
Farmington Hills, Michigan, Förenta staterna, 48334
- Michigan Center of Medical Research
-
-
Montana
-
Billings, Montana, Förenta staterna, 59102
- St Vincent Frontier Cancer Center
-
-
New York
-
Nyack, New York, Förenta staterna, 10960
- Hematology Oncology Association of Rockland
-
The Bronx, New York, Förenta staterna, 10461
- Montefiore Medical Center
-
-
-
-
Uttarakhand
-
Rishikesh, Uttarakhand, Indien, 249203
- Novartis Investigative Site
-
-
West Bengal
-
Kolkata, West Bengal, Indien, 700014
- Novartis Investigative Site
-
-
-
-
BO
-
Bologna, BO, Italien, 40138
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italien, 00168
- Novartis Investigative Site
-
Roma, RM, Italien, 00133
- Novartis Investigative Site
-
-
TS
-
Trieste, TS, Italien, 34129
- Novartis Investigative Site
-
-
-
-
-
Kumamoto, Japan, 8600008
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 4538511
- Novartis Investigative Site
-
-
Osaka
-
Osaka, Osaka, Japan, 5400006
- Novartis Investigative Site
-
Suita, Osaka, Japan, 5650871
- Novartis Investigative Site
-
-
Yamanashi
-
Kofu, Yamanashi, Japan, 4008506
- Novartis Investigative Site
-
-
-
-
-
Beijing, Kina, 100730
- Novartis Investigative Site
-
Jinan, Kina, 250012
- Novartis Investigative Site
-
Tianjin, Kina, 300020
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510515
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Novartis Investigative Site
-
-
Shandong
-
Binzhou, Shandong, Kina, 256603
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310003
- Novartis Investigative Site
-
-
-
-
-
George Town, Malaysia, 10050
- Novartis Investigative Site
-
Johor Bahru, Malaysia, 80100
- Novartis Investigative Site
-
Kuala Selangor, Malaysia, 68000
- Novartis Investigative Site
-
-
Pulau Pinang
-
George Town, Pulau Pinang, Malaysia, 10450
- Novartis Investigative Site
-
-
Sabah
-
Kota Kinabalu, Sabah, Malaysia, 88586
- Novartis Investigative Site
-
-
Selangor
-
Subang Jaya, Selangor, Malaysia, 47500
- Novartis Investigative Site
-
-
-
-
Coahuila
-
Saltillo, Coahuila, Mexiko, 25230
- Novartis Investigative Site
-
-
Michoacán
-
Morelia, Michoacán, Mexiko, 58260
- Novartis Investigative Site
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexiko, 64460
- Novartis Investigative Site
-
-
-
-
-
Utrecht, Nederländerna, 3584 CX
- Novartis Investigative Site
-
-
South Holland
-
Leiden, South Holland, Nederländerna, 2333 ZA
- Novartis Investigative Site
-
-
-
-
-
Timișoara, Rumänien, 300079
- Novartis Investigative Site
-
-
Dolj
-
Craiova, Dolj, Rumänien, 200136
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 119074
- Novartis Investigative Site
-
Singapore, Singapore, 169608
- Novartis Investigative Site
-
-
-
-
-
Salamanca, Spanien, 37007
- Novartis Investigative Site
-
-
A Coruna
-
Santiago Compostela, A Coruna, Spanien, 15706
- Novartis Investigative Site
-
-
-
-
-
London, Storbritannien, W12 0HS
- Novartis Investigative Site
-
London, Storbritannien, E1 1BB
- Novartis Investigative Site
-
Oxford, Storbritannien, OX3 7LE
- Novartis Investigative Site
-
-
-
-
-
Jeollanam, Sydkorea, 519763
- Novartis Investigative Site
-
Seoul, Sydkorea, 06591
- Novartis Investigative Site
-
-
-
-
-
Taoyuan, Taiwan, 33305
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10700
- Novartis Investigative Site
-
Chiang Mai, Thailand, 50200
- Novartis Investigative Site
-
-
-
-
-
Brno, Tjeckien, 625 00
- Novartis Investigative Site
-
Prague, Tjeckien, 128 08
- Novartis Investigative Site
-
Prague, Tjeckien, 100 34
- Novartis Investigative Site
-
-
-
-
-
Izmir, Turkiet (Türkiye), 35100
- Novartis Investigative Site
-
-
Atakum
-
Samsun, Atakum, Turkiet (Türkiye), 55200
- Novartis Investigative Site
-
-
Bilkent Cankaya
-
Ankara, Bilkent Cankaya, Turkiet (Türkiye), 06800
- Novartis Investigative Site
-
-
Efeler
-
Aydin, Efeler, Turkiet (Türkiye), 09100
- Novartis Investigative Site
-
-
Fatih
-
Istanbul, Fatih, Turkiet (Türkiye), 34098
- Novartis Investigative Site
-
-
-
-
-
Dresden, Tyskland, 01307
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Tyskland, 50937
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Tyskland, 01307
- Novartis Investigative Site
-
-
Thuringia
-
Jena, Thuringia, Tyskland, 07740
- Novartis Investigative Site
-
-
-
-
-
Budapest, Ungern, 1083
- Novartis Investigative Site
-
-
Hajdu Bihar Megye
-
Debrecen, Hajdu Bihar Megye, Ungern, 4032
- Novartis Investigative Site
-
-
-
-
-
Vienna, Österrike, 1090
- Novartis Investigative Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion criteria
- Male or female patients aged 18 years and older on the day of signing the informed consent.
- A signed informed consent must be obtained prior to participation in the study.
- A diagnosis of primary ITP, with insufficient response to, or relapse after a first-line corticosteroid therapy ± IVIG.
- Patient with platelet count <30G/L (whom eltrombopag is clinically indicated as per physician's discretion) and with no contraindication to receive eltrombopag
Key Exclusion criteria
- ITP patients who received second-line ITP treatments (other than steroid therapy± IVIG) including splenectomy. However, patients exposed to thrombopoietin receptor agonists (TPO-RAs) for a limited time (max one week) before screening are eligible.
- Patients with key lab abnormalities and patients with Evans syndrome or any other cytopenia, (patients with low grade anemia related to bleeding or iron deficiency are eligible).
- Patients with history of clinically significant hematological disorders, or with marked altered hematologic parameters
- Patients with current or history of life-threatening bleeding
- Patient that are Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B surface Antigen (HBsAg)/ Hepatitis B core antibody (HBcAb)-positive. HBcAb-positive patients can be enrolled if HBsAg negative, HBV DNA negative, no pre-existing liver fibrosis is present and antiviral prophylaxis is given
- Patients with known active or uncontrolled infection requiring systemic treatment during screening period
- Patients with hepatic impairment
- Patients with concurrent coagulation disorders and/or receiving antiplatelet or anticoagulant medication with an exemption of low dose of acetylsalicylic acid (≤150 mg daily)
- Nursing (breast feeding) or pregnant women
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment arm 1 - Lower dose
Participants will receive eltrombopag and ianalumab lower dose |
Concentrate for solution for infusion for intravenous use
Andra namn:
Film-coated tablet for oral use
Andra namn:
|
|
Experimentell: Treatment arm 2 - Higher dose
Participants will receive eltrombopag and ianalumab higher dose |
Concentrate for solution for infusion for intravenous use
Andra namn:
Film-coated tablet for oral use
Andra namn:
|
|
Placebo-jämförare: Treatment arm 3 - Placebo
Participants will receive eltrombopag and placebo |
Film-coated tablet for oral use
Andra namn:
Concentrate for solution for infusion for intravenous use. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time from randomization until treatment failure
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Time from randomization until treatment failure is defined as the time from randomization date until the first of the following events indicative of treatment failure:
|
Randomization to until end of study (up to 39 months after randomization of last participant)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Stable response at 6 months (Key Secondary Endpoint)
Tidsram: At 6 months
|
Percentage of participants with at least 3 platelet count collected at month 6 (between study days 121 and 183 and at least 75% of platelet counts qualified as a response). |
At 6 months
|
|
Complete Response rate at each timepoint
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Percentage of participants with any platelet count of at least 100 G/L in the absence of rescue treatment or new ITP treatment |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
Response rate at each timepoint
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Percentage of participants with any platelet count of at least 50 G/L in the absence of rescue treatment or new ITP treatment |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
Best response rate across all timepoints
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Percentage of participants with a best response rate of either response or complete response |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
Time to first response/time to first complete response
Tidsram: Time from randomization up to the longest observed treatment period duration
|
Time from randomization to date of first response and time from randomization to date of first complete response |
Time from randomization up to the longest observed treatment period duration
|
|
Duration of response
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Time from achievement of response to treatment failure. |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
Stable response at 1 year
Tidsram: At 1 year
|
Percentage of participants with at least 2 platelet count collected at year 1 (between study days 296 and 379 and at least 66% of platelet counts qualified as a response). |
At 1 year
|
|
Duration of complete response
Tidsram: Randomization to end of study (up to 39 months after randomization of last participant)
|
Time from achievement of complete response to loss of complete response stable response at 1 year period |
Randomization to end of study (up to 39 months after randomization of last participant)
|
|
Rate of participants who successfully taper and discontinue eltrombopag in each treatment arm
Tidsram: up to week 24
|
Probability to be treatment failure-free (as defined for the primary efficacy endpoint) |
up to week 24
|
|
Percentage of participants with bleeding events according to World Health Organization (WHO)
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Percentage of participants reporting bleeding events according to WHO bleeding scale |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
Number of participants receiving rescue treatment
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Number of participants who are in need of rescue treatment in each treatment arm |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
Percentage of participants receiving rescue treatment
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Percentage of participants who are in need of rescue treatment |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
Change from baseline in the frequency of CD19+ B-cell counts
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Post-baseline frequency of CD19+ B-cell counts (percentage within CD45) compared to baseline |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
Change from baseline in the absolute number of CD19+ B-cell counts
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Post-baseline absolute number of CD19+ B-cell counts compared to baseline |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
Change from baseline on T-score of the PROMIS SF v1.0 Fatigue 13a
Tidsram: From screening (baseline) until end of study (up 39 months after randomization of last participant)
|
The Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Fatigue 13a includes 13 items that assess fatigue in adults. |
From screening (baseline) until end of study (up 39 months after randomization of last participant)
|
|
Change from baseline in ITP PAQ domain scores of symptoms, fatigue, bother (uncomfortable), activity
Tidsram: From screening (baseline) until end of study (up 39 months after randomization of last participant)
|
The ITP-PAQ is a 44 item scale for measuring HRQoL in adults with ITP across ten scales: Symptoms, Bother-Physical Health, Fatigue/Sleep, Activity, Fear, Psychological Health, Work, Social Activity, Women´s Reproductive Health, overall QoL. Each item is rated on a Likert type scale. Each scale is scored from 0 to 100. Higher scores represent better HRQoL. |
From screening (baseline) until end of study (up 39 months after randomization of last participant)
|
|
Time to first occurence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
Change from baseline in immunoglobulins
Tidsram: Randomization to until end of study (up to 39 months after randomization of last participant)
|
Change from baseline in immunoglobulin levels |
Randomization to until end of study (up to 39 months after randomization of last participant)
|
|
PK parameters: AUClast
Tidsram: After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
|
AUClast: Area under the curve from time zero to the last measurable concentration sampling time (tlast) |
After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
|
|
PK parameters: AUCtau
Tidsram: After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
|
AUCtau: Area under the curve calculated to the end of a dosing interval (tau) |
After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
|
|
PK parameters: Cmax
Tidsram: After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
|
Maximum (peak) observed plasma, blood, serum or other body fluid drug concentration |
After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
|
|
PK parameters: Tmax
Tidsram: After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
|
Time to reach maximum (peak) observed plasma, blood, serum or other body fluid drug concentration |
After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
|
|
PK parameters: Accumulation ratio Racc
Tidsram: After last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
|
Accumulation ratio calculated using AUC values obtained after the last and first dose |
After last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
|
|
Incidence of anti-ianalumab antibodies in serum (ADA assay) over time
Tidsram: up to week 33
|
Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assessing the immunogenicity of ianalumab |
up to week 33
|
|
Titer of anti-ianalumab antibodies in serum (ADA assay) over time
Tidsram: up to week 33
|
Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assessing the immunogenicity of ianalumab |
up to week 33
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Cytopeni
- Patologiska processer
- Autoimmuna sjukdomar
- Immunsystemets sjukdomar
- Blödning
- Hudmanifestationer
- Hematologiska sjukdomar
- Blodkoagulationsstörningar
- Hemorragiska störningar
- Blodplättssjukdomar
- Trombotiska mikroangiopatier
- Purpura, trombocytopenisk
- Purpura
- Trombocytopeni
- Patologiska tillstånd, tecken och symtom
- Tecken och symtom
- Hemiska och lymfsjukdomar
- Purpura, Trombocytopenisk, Idiopatisk
- eltrombopag
- ianalumab
Andra studie-ID-nummer
- CVAY736Q12301
- 2024-512890-28-00 (Annan identifierare: EU CTIS)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .